作者
Minkyu Kim, Jisoo Park, Mehdi Bouhaddou, Kyumin Kim, Ajda Rojc, Maya Modak, Margaret Soucheray, Michael J McGregor, Patrick O’Leary, Denise Wolf, Erica Stevenson, Tzeh Keong Foo, Dominique Mitchell, Kari A Herrington, Denise P Muñoz, Beril Tutuncuoglu, Kuei-Ho Chen, Fan Zheng, Jason F Kreisberg, Morgan E Diolaiti, John D Gordan, Jean-Philippe Coppé, Danielle L Swaney, Bing Xia, Laura van’t Veer, Alan Ashworth, Trey Ideker, Nevan J Krogan
发表日期
2021/10/1
期刊
Science
卷号
374
期号
6563
页码范围
eabf3066
出版商
American Association for the Advancement of Science
简介
INTRODUCTION
Advances in DNA sequencing technology have enabled the widespread analysis of breast tumor genomes, creating a catalog of genetic mutations that may initiate or drive tumor progression. In addition to common mutations in well-known cancer genes, such as TP53 and PIK3CA, breast cancers harbor a variety of rare mutations with low prevalence across the patient population. Despite this heterogeneity, the majority of breast cancer patients are treated using broad chemotherapy or hormone therapies, which vary widely in effectiveness across patients. Therefore, there is an urgent need to develop targeted therapies matched to the specific molecular alterations in each patient’s tumor, with the goal of improving efficacy, reducing toxicity, and avoiding unnecessary treatment.
RATIONALE
A key question is how these rare alterations elicit pathologic consequences, control patient outcomes, and …
学术搜索中的文章
M Kim, J Park, M Bouhaddou, K Kim, A Rojc, M Modak… - Science, 2021